logo
  

SAF-Holland Buys IMS Group

SAF-Holland SE (SFQ.DE), a chassis related components manufacturer, Wednesday announced that it has acquired the Netherlands based IMS Group B.V., for a purchase price in low single-digit million euro range.

On completion of acquisition, the company intends to use IMS Group's environmentally friendly technologies to strengthen and expand its market position in the Netherlands, Belgium and Luxembourg.

IMS Group, which currently has 38 employees, was acquired from its former exclusive distribution partner Pon Group, the company said in a statement.

Currently, SAF-Holland's stock is trading at 15.29 euros, down 1.23% on the XETRA.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Home improvement major Lowe's Companies, Inc. on Tuesday maintained its fiscal 2024 earnings and sales outlook after reporting weak results in its first quarter. However, the quarterly earnings per share were above market estimates. In pre-market activity on the NYSE, Lowe's shares were gaining around 3.1 percent... Veolia (VE) announced Tuesday that its consulting engineering and strategic and operational assistance division Seureca announced the acquisition of MRC Consultants and Transaction Advisers. The financial aspects of the deal are not revealed. The combination of MRC, an energy consulting firm in Spain... French drug major Sanofi is teaming with artificial intelligence or AI startup OpenAI, the developer of highly popular generative AI chatbot ChatGPT, as well as Formation Bio, an AI and tech-driven drug developer, to build AI-powered software to accelerate drug development and bring new medicines more efficiently.

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
RELATED NEWS
Follow RTT